Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
ACE Reports
(100 Reports)
ACE Reports
Our Al driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Metabolic Disorders
The effect of adjuvant aromatase inhibitors on BMD in women with breast cancer
Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
The effect of adjuvant aromatase inhibitors on BMD in women with breast cancer
Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11
Metabolic Disorders
Better clinicoradiological results at 3 years with SpineJack vertebral augmentation vs BPK for VCFs
Osteoporos Int. 2019 Mar;30(3):637-645. doi: 10.1007/s00198-018-4773-5
Better clinicoradiological results at 3 years with SpineJack vertebral augmentation vs BPK for VCFs
Osteoporos Int. 2019 Mar;30(3):637-645. doi: 10.1007/s00198-018-4773-5
Metabolic Disorders
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
Arthroplasty
Periprosthetic bone loss post-total hip arthroplasty mitigated by bisphosphonate therapy
J Orthop Surg Res. 2018 Sep 4;13(1):225. doi: 10.1186/s13018-018-0918-7
Periprosthetic bone loss post-total hip arthroplasty mitigated by bisphosphonate therapy
J Orthop Surg Res. 2018 Sep 4;13(1):225. doi: 10.1186/s13018-018-0918-7
Metabolic Disorders
Adherence to weekly oral BP therapy versus quarterly IV BP therapy at varying health literacy level
J Bone Miner Metab. 2018 Sep;36(5):589-595. doi: 10.1007/s00774-017-0867-y
Adherence to weekly oral BP therapy versus quarterly IV BP therapy at varying health literacy level
J Bone Miner Metab. 2018 Sep;36(5):589-595. doi: 10.1007/s00774-017-0867-y
Metabolic Disorders
Incidence of falls reduced following balance training in patients with osteoporosis
J Rehabil Med. 2018 Jul 17;50(7):577-581. doi: 10.2340/16501977-2334
Incidence of falls reduced following balance training in patients with osteoporosis
J Rehabil Med. 2018 Jul 17;50(7):577-581. doi: 10.2340/16501977-2334
Metabolic Disorders
Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis
Climacteric. 2018 Apr;21(2):189-195
Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis
Climacteric. 2018 Apr;21(2):189-195
Metabolic Disorders
Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls
Expert Opin Drug Saf. 2018 Apr;17(4):413-428
Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls
Expert Opin Drug Saf. 2018 Apr;17(4):413-428
Metabolic Disorders
Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture
Osteoporos Int. 2016 Nov;27(11):3289-3300
Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture
Osteoporos Int. 2016 Nov;27(11):3289-3300
Metabolic Disorders
AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women
AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women
General Orthopaedics
Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543
Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543
Metabolic Disorders
The effect of eldecalcitol on balence and strength in women with osteoporosis
J Bone Miner Metab. 2016 Sep;34(5):547-54
The effect of eldecalcitol on balence and strength in women with osteoporosis
J Bone Miner Metab. 2016 Sep;34(5):547-54
Metabolic Disorders
Immediate effects on bone metabolism biomarkers noted with resistance training and walking
BMC Musculoskelet Disord. 2016 Jun 8;17(1):254
Immediate effects on bone metabolism biomarkers noted with resistance training and walking
BMC Musculoskelet Disord. 2016 Jun 8;17(1):254
Metabolic Disorders
Efficacy of zoledronic acid following PLIF in patients with osteoporosis
Osteoporos Int. 2016 Apr;27(4):1469-76
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Efficacy of zoledronic acid following PLIF in patients with osteoporosis
Osteoporos Int. 2016 Apr;27(4):1469-76
Metabolic Disorders
Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis
J Clin Endocrinol Metab. 2016 May;101(5):2023-30
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis
J Clin Endocrinol Metab. 2016 May;101(5):2023-30
Metabolic Disorders
Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users
Osteoporos Int. 2016 Jun;27(6):1989-98
Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users
Osteoporos Int. 2016 Jun;27(6):1989-98
Metabolic Disorders
Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70
Metabolic Disorders
Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies
J Clin Densitom. 2016 Jul-Sep;19(3):346-51
Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies
J Clin Densitom. 2016 Jul-Sep;19(3):346-51
Metabolic Disorders
No effect of GLP-1 receptor agonists on fracture incidence in type 2 diabetes treatment
J Diabetes. 2014 May;6(3):260-6. doi: 10.1111/1753-0407.12102. Epub 2013 Nov 22
No effect of GLP-1 receptor agonists on fracture incidence in type 2 diabetes treatment
J Diabetes. 2014 May;6(3):260-6. doi: 10.1111/1753-0407.12102. Epub 2013 Nov 22
Metabolic Disorders
Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.
Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.
Showing 1-20 of 100 results
1
2
3
4
5